Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Cash Flow (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Net Cash Flow for 4 consecutive years, with $23.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 1129.55% to $23.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.4 million, a 151.37% increase, with the full-year FY2024 number at -$8.3 million, down 177.01% from a year prior.
  • Net Cash Flow was $23.3 million for Q3 2025 at Orchestra BioMed Holdings, up from $401000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $77.6 million in Q2 2022 to a low of -$77.2 million in Q4 2022.
  • A 4-year average of $2.1 million and a median of $389000.0 in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 564.37% in 2024, then skyrocketed 1129.55% in 2025.
  • Orchestra BioMed Holdings' Net Cash Flow stood at -$77.2 million in 2022, then surged by 114.87% to $11.5 million in 2023, then tumbled by 129.13% to -$3.3 million in 2024, then skyrocketed by 795.66% to $23.3 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Net Cash Flow are $23.3 million (Q3 2025), $401000.0 (Q2 2025), and -$3.9 million (Q1 2025).